01—Abstract
Summary
Summary of the 8-K filed February 8, 2024. Cited figures are marked; the original filing is the authoritative source.
DexCom reported Q4 and full-year 2023 results that were strong on both top and bottom lines.
Q4 revenue grew 27% to $1.03 billiona (26% organic), with U.S. and international each up 27% on a reported basis. Full-year revenue rose 24% to $3.62 billion, and GAAP operating margin expanded 310 basis points to 16.5%. Growth was driven mainly by volume and strong new customer additions as awareness of real-time CGM increases.
Sensor and other revenue grew 32% in Q4, while hardware revenue fell 13%, consistent with a shift toward recurring sensor sales. Profitability improved meaningfully. Q4 GAAP operating income was $216.9 millionb (21.0% of revenue), up 560 basis points year over year, and Q4 GAAP diluted EPS was $0.62 versus $0.22.
Q4 GAAP net income benefited from a $78.4 millionc tax adjustment (largely related to the Verily milestone payment), so non-GAAP diluted EPS of $0.50 is a cleaner comparison point. Full-year non-GAAP EPS was $1.52 versus $0.87 in 2022. The company ended the year with $2.72 billion in cash and marketable securities and an undrawn revolver, while total debt rose to roughly $2.4 billion of long-term convertible notes after the 2023 notes matured.
For 2024, DexCom reiterated revenue, non-GAAP gross margin and non-GAAP operating margin guidance and introduced adjusted EBITDA margin guidance of about 29%. Revenue guidance of $4.15 to $4.35 billiond implies 16% to 21% organic growth, a deceleration from 2023's pace.
Investors will likely focus on whether the G7 rollout, Stelo (type 2 non-insulin sensor) and direct-to-watch approvals can sustain that growth. Note that this 8-K furnishes the press release under Item 2.02 and is not deemed filed under the Exchange Act.
02—Key points
Key Highlights
- Q4 2023 revenue rose 27% year over year to $1.03 billion (26% organic), led by volume growth and record new customer starts.
- Full-year 2023 revenue grew 24% to $3.62 billion; GAAP operating margin reached 16.5%, up 310 bps, and non-GAAP operating margin reached 19.8%.
- Q4 GAAP diluted EPS was $0.62 (vs. $0.22), but includes a $78.4M tax adjustment; non-GAAP diluted EPS was $0.50 (vs. $0.34).
- Sensor and other revenue grew 32% in Q4 to $947.0M, while hardware revenue declined 13%, reflecting a shift toward recurring sensor income.
- 2024 guidance: revenue of $4.15–4.35B (16–21% organic growth), non-GAAP gross margin of 63–64%, non-GAAP operating margin of ~20%, and new adjusted EBITDA margin guidance of ~29%.
- Cash, equivalents and marketable securities totaled $2.72B at year-end with the revolving credit facility undrawn, though long-term convertible notes rose to $2.43B.
- Submitted Stelo (type 2 non-insulin sensor) and direct-to-watch features to the FDA for review, which are key potential growth drivers for 2024.
03—Questions
Frequently Asked Questions
How strong was DexCom's revenue growth in Q4 and full-year 2023?
Q4 2023 revenue grew 27% to $1.03 billion on a reported basis (26% organic), and full-year revenue grew 24% to $3.62 billion. U.S. and international growth were both strong, with international full-year growth at 30%.
Why do GAAP and non-GAAP EPS differ so much in Q4 2023?
GAAP diluted EPS of $0.62 was boosted by a $78.4 million tax benefit, primarily tied to the Verily sales-based milestone payment. Non-GAAP diluted EPS of $0.50 excludes this and other items such as intangible amortization and litigation costs, providing a clearer view of operating performance.
What is DexCom's 2024 outlook?
DexCom expects 2024 revenue of $4.15–4.35 billion, representing 16–21% organic growth, with non-GAAP gross margin of 63–64%, non-GAAP operating margin near 20%, and adjusted EBITDA margin near 29%. Revenue growth is expected to moderate from 2023's pace.
Is DexCom's balance sheet able to fund its growth plans?
Yes, DexCom held $2.72 billion in cash and marketable securities at year-end, and its revolving credit facility was undrawn. Management cited this liquidity as supporting continued production capacity expansion and new market opportunities, though convertible debt on the balance sheet increased to about $2.4 billion.
What product developments could drive future growth?
Pending FDA reviews include Stelo, a glucose sensor for people with type 2 diabetes who do not use insulin, and a direct-to-watch feature allowing smartwatches to serve as the primary receiver. Pump integrations with Tandem t:slim X2 and Beta Bionics iLet were also advanced.
04—Continue